A Single Arm Phase II Study Osimertinib in Patients with Stage 4 Non-small Cell Lung Cancer with Uncommon EGFR Mutations Thoracic Oncology Program (TOP) Protocol Number: TOP 1703
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca LP
Start Date
April 30, 2018
End Date
April 30, 2023
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca LP
Start Date
April 30, 2018
End Date
April 30, 2023